Book Appointment
Book Appointment

What “stem cell therapy” means in orthopedics (short)

Most orthopaedic “stem-cell” treatments use mesenchymal stromal/stem cells (MSCs) or concentrated bone-marrow/adipose cell fractions. In practice these treatments are usually delivered as:

  • Bone marrow aspirate concentrate (BMAC) (point-of-care concentrate from iliac crest),
  • Adipose-derived stromal vascular fraction (SVF) or micro-fragmented adipose tissue,
  • Culture-expanded MSCs (cells grown in a lab to increase numbers), or
  • Allogeneic “off-the-shelf” MSC products (donor-derived).
    Mechanistically MSCs act largely by paracrine and immunomodulatory effects (growth factors, cytokines) that reduce inflammation and stimulate local repair rather than by permanently becoming new cartilage or tendon in large numbers

How they’re thought to help (mechanisms)

  • Anti-inflammatory / immunomodulation: MSCs lower local inflammation which can reduce pain and slow degeneration. Nature
  • Paracrine trophic effects: MSCs secrete growth factors that recruit local cells, promote angiogenesis and matrix production. PMC
  • Differentiation (limited): In some settings MSCs can differentiate toward bone/cartilage/tendon cells, but long-term engraftment is uncommon — most benefit appears driven by secreted factors. 

Realistic indications in orthopedics — what the literature actually shows

Important bottom-line: No mainstream orthopaedic condition is universally “cured” by stem cells. Evidence ranges from promising (symptom relief, structural signals) to mixed or insufficient. Use of stem cells should be discussed as evidence-based but often investigational for many indications.

Below are common orthopaedic indications with a plain-language summary + the evidence level.

1. Knee osteoarthritis (OA)

  • What clinicians see: Multiple randomized trials and meta-analyses report short-to-mid-term improvements in pain and function after intra-articular MSC or BMAC injections (weeks–12 months). However study methods vary widely and long-term structural cartilage regeneration remains uncertain. Systematic reviews (including recent Cochrane / meta-analyses) conclude results are promising but heterogeneous and more high-quality trials are needed. Best candidates tend to be younger patients with early–moderate OA (KL II–III), not end-stage OA. cochranelibrary.com+2PMC+2

2. Focal cartilage defects & cartilage repair (e.g., post-traumatic chondral lesions)

  • Evidence: Clinical series and small trials (including culture-expanded MSCs combined with scaffolds or microfracture) show improved symptoms and some MRI/arthroscopic evidence of repair. These are promising for focal defects (as an adjunct to microfracture/ACI techniques) but results vary by technique and lesion size. Longer follow-up and comparative RCTs remain limited. PMC+1

3. Meniscal injuries (after partial meniscectomy / meniscal repair)

  • Evidence: Small randomized and pilot studies (e.g., Vangsness et al.) reported increased meniscal volume on MRI and improved pain in some patients after intra-articular MSC injections. This suggests potential to improve meniscal healing in select cases — still early evidence. PubMed+1

4. Rotator cuff and tendon injuries

  • Evidence: Preclinical and clinical studies indicate MSC augmentation (injection or biologic augmentation at repair) can reduce re-tear rates and improve healing quality in some series; randomized data are still limited but growing. These are promising as an adjunct to surgical repair, not as a guaranteed standalone cure. PMC+1

5. Avascular necrosis (osteonecrosis) of femoral head (early stage)

  • Evidence: Combining core decompression with implantation of bone-marrow derived cells (BMMNC/BMAC/MSCs) has shown reduced progression to collapse and lower conversion to arthroplasty in several meta-analyses for early/pre-collapse disease. Best outcomes are in early (pre-collapse) stages. PubMed+1

6. Fracture non-union / delayed union & bone defects

  • Evidence: Clinical pilot studies and small trials show improved bone healing rates for some non-unions when cell therapy (autologous or allogeneic bone-forming cells) is used percutaneously or with scaffolds — data are promising but heterogeneous and not uniformly superior to standard grafting in all series. BioMed Central+1

7. Ligament (ACL) augmentation and graft healing

  • Evidence: Preclinical data are strong; human trials show safety and some biological signals of improved graft maturation, but consistent clinical superiority (reduced laxity or better functional outcomes) has not been definitively proven yet. Most use is still investigational/adjunctive.